Related Experiment Videos
Ceftriaxon in the treatment of severe bacterial infections
Insights
Ceftriaxone (Rocephin) showed good clinical efficacy in 16 of 17 patients with appendicitis or severe infections. Laboratory monitoring is advised for Pseudomonas aeruginosa infections during ceftriaxone therapy.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Ceftriaxone (Rocephin) is a third-generation cephalosporin antibiotic.
- Severe infections and diffuse purulent appendicitis require effective antimicrobial therapy.
- Mixed aerobic and anaerobic microbial flora are common in intra-abdominal infections.
Purpose of the Study:
- To evaluate the clinical efficacy of ceftriaxone therapy.
- To assess the tolerability and laboratory alterations during ceftriaxone treatment.
- To investigate the need for laboratory monitoring in specific severe infections.
Main Methods:
- Prospective study of two patient groups.
- Group 1: 10 children with purulent appendicitis (mixed flora).
- Group 2: 7 patients with severe aerobic pathogen infections.
- Bacteriological sensitivity testing (disc method) and serum bactericidal capacity titration were performed.
Main Results:
- Good clinical response in 16 out of 17 patients.
- High in vitro sensitivity to ceftriaxone observed for aerobic pathogens.
- Serum bactericidal capacity monitoring indicated potential issues with Pseudomonas aeruginosa.
- Parenteral ceftriaxone was generally well-tolerated.
Conclusions:
- Ceftriaxone demonstrates significant clinical efficacy in treating purulent appendicitis and severe aerobic infections.
- Laboratory monitoring of serum bactericidal activity is recommended for infections caused by Pseudomonas aeruginosa.
- Ceftriaxone is a well-tolerated antibiotic for these indications.
Abstract:
The efficacy of ceftriaxon (Rocephin Roche) therapy has been studied by our team in two groups of patients. The first one consisted of 10 children suffering from a diffuse purulent appendical peritonitis brought about by a mixed aerobe and anaerobe microbial flora, the second one comprising 7 patients with severe infections caused by problematic aerobe pathogens. The clinical effect of the treatment was good in 16 out of the 17 cases, in one patient it could not be evaluated. Even though a high degree of sensitivity to Rocephin could be demonstrated bacteriologically by the disc method in all the aerobe germs present, the results of titration of the bactericide capacity of the sera during treatment indicate the need for laboratory monitoring of the course of therapy of severe infections due to pseudomonas aeruginosa. Parenteral administration of Rocephin was well tolerated and the laboratory alterations seemin the course of therapy of severe infections due to Pseudomonas aeruginosa. Parenteral administration of Recephin was well tolerated and the laboratory alterations seen in the postoperative ileus due to strangulation and adhesions--cannot be recommended.